Healthy cells migrate only under special circumstances, such as in the early development of an embryo or when new skin cells and blood vessels move in to repair a wound. For a cancer cell to gain access to the body’s major highways -- the blood vessels and lymphatic system -- it has to invade through something.
University of Michigan Rogel Cancer Center breast cancer researchers discuss the amazing progress of breast cancer research over the past decades and look ahead to the day when it's understood exactly how and why breast cancer spreads so it can be stopped.
Regulatory T cells, or Treg cells, work within the immune system to suppress immune function. Cancer immunotherapy treatments work by supercharging the immune system to fight cancer. So when Tregs come in and suppress the immune response, it shuts down the cancer-fighting effect. But eliminating the Tregs doesn’t help. Researchers have tried, but a clinical trial testing that idea showed no benefit to patients.
Honeycomb-like arrays of tiny, lab-grown cancers could one day help doctors zero in on individualized treatments for ovarian cancer, an unpredictable disease that kills more than 14,000 women each year in the United States alone.
Research has shown that whether or not a patient is married makes a difference in how well -- or not -- a patient does, including for patients with cancer. What researchers don't understand is exactly why being married makes such a difference.
Even 20 years after a diagnosis, women with a type of breast cancer fueled by estrogen still face a substantial risk of cancer returning or spreading, according to a new analysis from an international team of investigators published in the New England Journal of Medicine.
According to new research by Michigan Medicine, more than 10 percent of people who had never taken opioids prior to curative-intent surgery for cancer continued to take the drugs three to six months later. The risk is even greater for those who are treated with chemotherapy after surgery.
Women who pursue a more aggressive surgery for early stage breast cancer have nearly eight times the odds of reporting substantial employment disruptions, according to a new study from University of Michigan Rogel Cancer Center researchers.
The Stanford Medicine Alumni Association has announced that Max S. Wicha, M.D., will receive the prestigious J. E. Wallace Sterling Lifetime Achievement Award in Medicine. He will be honored at a dinner held on the Stanford School of Medicine campus on December 9.
A new study finds doctors are appropriately using a genetic test to measure breast cancer recurrence risk and to make tailored treatment recommendations.